Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of fosmanogepix for invasive mold infections
MOH_2025-08-27_014299Phase 3Not yet recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fosmanogepix in Invasive Mold Infections (IMIs), invasive aspergillosis (IA), invasive fusariosis (IF) and 2 more (3 cohorts), sponsored by Basilea Pharmaceutica. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
fosmanogepix
03
Conditions
Invasive Mold Infections (IMIs)invasive aspergillosis (IA)invasive fusariosis (IF)lomentosporiosismucormycosis
Beyond the preview
Go deeper on MOH_2025-08-27_014299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-08-27_014299.